Boger DL - Search Results

1

CBI-CDPBO1 and CBI-CDPBI1: CC-1065 analogs containing deep-seated modifications in the DNA binding subunit.

Boger DL, Yun W, Cai H, Han N. Boger DL, et al. Bioorg Med Chem. 1995 Jun;3(6):761-7. doi: 10.1016/0968-0896(95)00066-p. Bioorg Med Chem. 1995. PMID: 7582954

2

Demonstration of a pronounced effect of noncovalent binding selectivity on the (+)-CC-1065 DNA alkylation and identification of the pharmacophore of the alkylation subunit.

Boger DL, Zarrinmayeh H, Munk SA, Kitos PA, Suntornwat O. Boger DL, et al. Proc Natl Acad Sci U S A. 1991 Feb 15;88(4):1431-5. doi: 10.1073/pnas.88.4.1431. Proc Natl Acad Sci U S A. 1991. PMID: 1847523 Free PMC article.

3

Streptonigrin and lavendamycin partial structures. Probes for the minimum, potent pharmacophore of streptonigrin, lavendamycin, and synthetic quinoline-5,8-diones.

Boger DL, Yasuda M, Mitscher LA, Drake SD, Kitos PA, Thompson SC. Boger DL, et al. J Med Chem. 1987 Oct;30(10):1918-28. doi: 10.1021/jm00393a040. J Med Chem. 1987. PMID: 3656364

4

CC-1065 CBI analogs: an example of enhancement of DNA alkylation efficiency through introduction of stabilizing electrostatic interactions.

Boger DL, Yun W, Han N, Johnson DS. Boger DL, et al. Bioorg Med Chem. 1995 Jun;3(6):611-21. doi: 10.1016/0968-0896(95)00048-l. Bioorg Med Chem. 1995. PMID: 7582940

5

CC-1065 and the duocarmycins: unraveling the keys to a new class of naturally derived DNA alkylating agents.

Boger DL, Johnson DS. Boger DL, et al. Proc Natl Acad Sci U S A. 1995 Apr 25;92(9):3642-9. doi: 10.1073/pnas.92.9.3642. Proc Natl Acad Sci U S A. 1995. PMID: 7731958 Free PMC article. Review.

6

Molecular basis for sequence selective DNA alkylation by (+)- and ent-(-)-CC-1065 and related agents: alkylation site models that accommodate the offset AT-rich adenine N3 alkylation selectivity.

Boger DL, Johnson DS, Yun W, Tarby CM. Boger DL, et al. Bioorg Med Chem. 1994 Feb;2(2):115-35. doi: 10.1016/s0968-0896(00)82007-6. Bioorg Med Chem. 1994. PMID: 7922122

7

Design, synthesis and evaluation of bouvardin, deoxybouvardin and RA-I-XIV pharmacophore analogs.

Boger DL, Patane MA, Jin Q, Kitos PA. Boger DL, et al. Bioorg Med Chem. 1994 Feb;2(2):85-100. doi: 10.1016/s0968-0896(00)82005-2. Bioorg Med Chem. 1994. PMID: 7922127

8

Evaluation of functional analogs of CC-1065 and the duocarmycins incorporating the cross-linking 9a-chloromethyl-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-on e (C2BI) alkylation subunit.

Boger DL, Johnson DS, Palanki MS, Kitos PA, Chang J, Dowell P. Boger DL, et al. Bioorg Med Chem. 1993 Jul;1(1):27-38. doi: 10.1016/s0968-0896(00)82100-8. Bioorg Med Chem. 1993. PMID: 8081835

9

Total synthesis and biological properties of novel antineoplastic (chloromethyl)furanoindolines: an asymmetric hydroboration mediated synthesis of the alkylation subunits.

Mohamadi F, Spees MM, Staten GS, Marder P, Kipka JK, Johnson DA, Boger DL, Zarrinmayeh H. Mohamadi F, et al. Among authors: boger dl. J Med Chem. 1994 Jan 21;37(2):232-9. doi: 10.1021/jm00028a005. J Med Chem. 1994. PMID: 8295210

10

Synthesis of key analogs of bleomycin A2 that permit a systematic evaluation of the linker region: identification of an exceptionally prominent role for the L-threonine substituent.

Boger DL, Colletti SL, Teramoto S, Ramsey TM, Zhou J. Boger DL, et al. Bioorg Med Chem. 1995 Sep;3(9):1281-95. doi: 10.1016/0968-0896(95)00113-u. Bioorg Med Chem. 1995. PMID: 8564421

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

363 results

Search Page

Filters